Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 552, 120-127
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (20K22978, JP19127954)
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 32 references indexed in Scilit:
- Latest research and treatment of advanced-stage epithelial ovarian cancerNature Reviews Clinical Oncology, 2013
- Scaffold: A bioinformatic tool for validating MS/MS‐based proteomic studiesProteomics, 2010
- A prognostic gene expression index in ovarian cancer—validation across different independent data setsThe Journal of Pathology, 2009
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical OutcomeClinical Cancer Research, 2008
- Mevalonate pathway: A review of clinical and therapeutical implicationsClinical Biochemistry, 2007
- What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?Gynecologic Oncology, 2007
- Statin therapy and autoimmune disease: from protein prenylation to immunomodulationNature Reviews Immunology, 2006
- Fibroblast Growth Factor 9 Has Oncogenic Activity and Is a Downstream Target of Wnt Signaling in Ovarian Endometrioid AdenocarcinomasCancer Research, 2006
- A Genomic and Functional Inventory of Deubiquitinating EnzymesCell, 2005
- Inhibiting the p53–MDM2 interaction: an important target for cancer therapyNature Reviews Cancer, 2003